JW Pharmaceutical: Higher Profits and Low Multiples, With a Share Price Well Below Its 52-Week High

Thesis

The data supports a picture of improving profitability. Operating margin rose from 5.1% in 2021 to 13.9% on a trailing basis, and trailing net income of ₩101.3B is well above the ₩61.5B reported for 2025. Trailing ROE of 27.4% is high against the 17.6% of 2025. Free cash flow was ₩122.8B, above net income.

What the data does not settle is why the shares fell back from their high. Short-term trends are weak: the price is down 7.8% in one month, though it is up 4.3% over three months and 17.1% over one year. Foreign ownership slipped from 8.6% to 7.6% over 60 days, and 20-day foreign flows were slightly negative at about -₩1.4B. Institutions and retail investors were small net buyers. The recent filings include two amended fine notices, but their amounts and details are not in the data. No news headlines are available, so no reason for the price move can be drawn from them.

Business overview

JW Pharmaceutical is a KOSPI-listed company in the biotech and pharma sector, founded in 1945 and listed since 1976. It has 23,285,930 listed shares and a market capitalisation of ₩589.1B. It is run by two co-CEOs, Shin Young-seop and Ham Eun-kyung. Revenue grew from ₩606.6B in 2021 to ₩775.3B in 2025, with one down year in 2024 (-3.9%). The data contains no product or pipeline breakdown, so what drives sales is not available here.

Model estimate of fair value

Bear

₩24,644

+6%

Base

₩42,784

+85%

Bull

₩73,297

+217%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

• [Amended] Imposition of FinesOct 8, 2026
• Acquisition of shares in another companySep 29, 2026
• [Amended] Imposition of FinesSep 18, 2026
• Change in largest shareholder's holdingsSep 17, 2026
• 5%+ holding reportSep 17, 2026
• Insider shareholding reportSep 17, 2026
• Major management matter relevant to investorsAug 28, 2026
• Major management matter relevant to investorsAug 14, 2026
• Half-year report (Jun 2026)Aug 14, 2026
• Major management matter relevant to investorsAug 11, 2026
• Fair Trade Self-Compliance Program Operation Status (Informational Disclosure)Aug 11, 2026
• Preliminary earningsAug 11, 2026
• Daily prices up to 2026-10-16
• Financial statements, trailing 12 months as of H1 2026
• Our fair value model, statements as of TTM to H1 2026

Report history

1. Oct 25, 2026Update noteModel fair value changeJW Pharmaceutical: Model Fair Value Estimate Rises to ₩52,434 Base Case as Shares Slip to ₩23,900
2. Oct 18, 2026InitiationStart of coverage (reader request)JW Pharmaceutical: Higher Profits and Low Multiples, With a Share Price Well Below Its 52-Week High